A.P. Pharma raises $53.6mn to give long-acting granisetron a second NDA shot
This article was originally published in Scrip
A.P. Pharma is raising $53.6 million through a common stock offering to new and existing institutional investors to see if the second time is the charm for APF530, a reformulated 5-HT3 antagonist in development to treat delayed- and acute-onset chemotherapy-induced nausea and vomiting (CINV), which the company sees as a $900 million-per-year market.